Heberon Alfa R in COVID-19

Use of Heberon® Alfa R in patients confirmed for infection with SARS-CoV-2 in Cuba. Observational clinical study. (COVID-19)

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

RPCEC

Registry ID

RPCEC00000318

Enrollment

Unknown

Registered

2020-05-29

Start date

2020-03-11

Completion date

Unknown

Last updated

2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with confirmed SARS-CoV-2 infection COVID-19 SARS-CoV2

Interventions

IFN-a2b 3 million IU (Heberon® Alpha R), intramuscularly, 3 times per week, for 2 weeks

Interferon-alpha

Injections, Intramuscular

Heberon Alfa R

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. SARS-CoV-2 positive patients by rapid or confirmatory qPCR tests. 2. Informed consent granted.

Exclusion criteria

Exclusion criteria: 1. Patients with chronic decompensated diseases, or autoimmune-type diseases. 2. Known hypersensitivity to any of the components of the formulation under study. 3. No Informed consent granted.

Design outcomes

Primary

Measure	Time frame
Proportion of patients discharged from the hospital (Patients with clinical discharge of the confirmed case according to clinical, radiological and, laboratory criteria divided by the number of recruited patients). Measurement time: at the end of treatment (14 days). -Clinical criteria: The patient's condition is stable and afebrile for more than 3 days, regular breathing and normal respiratory rate, clear conscience, unaffected speech and normal diet. -Radiological criteria: Lung images show significant improvement without signs of organ dysfunction. -Laboratory criteria: Two consecutive negative respiratory pathogenic nucleic acid tests (at least one day between tests).	—

Measure

Time frame

Proportion of patients discharged from the hospital (Patients with clinical discharge of the confirmed case according to clinical, radiological and, laboratory criteria divided by the number of recruited patients). Measurement time: at the end of treatment (14 days). -Clinical criteria: The patient's condition is stable and afebrile for more than 3 days, regular breathing and normal respiratory rate, clear conscience, unaffected speech and normal diet. -Radiological criteria: Lung images show significant improvement without signs of organ dysfunction. -Laboratory criteria: Two consecutive negative respiratory pathogenic nucleic acid tests (at least one day between tests).

—

Secondary

Measure	Time frame
Case Fatality Rate-CFR (Number of confirmed deaths divided by the number of number of recruited patients). Measurement time: at the end of treatment (14 days).	—

Countries

Cuba

Contacts

Public ContactRicardo Pereda Gonzalez

Medical Science College of Havana

pereda.gonzalez@infomed.sld.cu

Outcome results

None listed

Source: RPCEC (via WHO ICTRP) · Data processed: Aug 15, 2026